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Abstract: New nanoparticles and biomaterials are increasingly being used in biomedical research
for drug delivery, diagnostic applications, or vaccines, and they are also present in numerous
commercial products, in the environment and workplaces. Thus, the evaluation of the safety and
possible therapeutic application of these nanomaterials has become of foremost importance for
the proper progress of nanotechnology. Due to economical and ethical issues, in vitro and in vivo
methods are encouraged for the testing of new compounds and/or nanoparticles, however in vivo
models are still needed. In this scenario, zebrafish (Danio rerio) has demonstrated potential for
toxicological and pharmacological screenings. Zebrafish presents an innate immune system, from
early developmental stages, with conserved macrophage phenotypes and functions with respect
to humans. This fact, combined with the transparency of zebrafish, the availability of models
with fluorescently labelled macrophages, as well as a broad variety of disease models offers great
possibilities for the testing of new nanoparticles. Thus, with a particular focus on macrophage–
nanoparticle interaction in vivo, here, we review the studies using zebrafish for toxicological and
biodistribution testing of nanoparticles, and also the possibilities for their preclinical evaluation in
various diseases, including cancer and autoimmune, neuroinflammatory, and infectious diseases.
Keywords: zebrafish; nanomaterial; nanoparticle; drug delivery; macrophage; immune system;
innate immunity
1. Introduction
Recent advances in nanotechnology offer the possibility to engineer a wide variety
of new nanoparticles and biomaterials with potential application in medicine, but also
with commercial interest, providing solutions for numerous sectors in society (i.e., electric-
ity, cosmetics, food packaging, etc.) [1,2]. There is considerable evidence that nano- and
microscale materials have unique biological interactions when compared with molecules
or bulk materials [3]. Thus, safety assessment results are, of course, of paramount im-
portance [4]. In the case of medical applications, nanomaterials are designed for drug
delivery, imaging, diagnosis, sensing, and/or therapeutic purposes. Thus, the benefit/risk
for the use of nanotechnologies in this case acquires a different dimension similar to the
pharmacological/toxicological profile of other drugs [5]. For these studies, in silico and
in vitro methods, including cell- and organ-based assays, are encouraged. However, animal
tests are still needed [4,6].
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In this context, the zebrafish (Danio rerio) has become a well-established model for the
toxicological and pharmacological screening of new drugs [7] and nanomaterials [8]. Rapid
embryo development, small size and transparency, genetic and physiological conservation,
ethical and economic advantages have made zebrafish stand out from all other in vivo
models [9]. Furthermore, the innate branch of the immune system, including macrophage
functions, is well-conserved between humans and the zebrafish, presenting a powerful
model for the study of immunotoxicity and also diseases causing and/or caused by in-
flammatory disorders (i.e., cancer, autoimmune diseases or infectious diseases) [10,11].
Several zebrafish models with fluorescently labeled macrophages have been developed and
optimized for studies with a particular focus on the role of macrophages in the toxicological
or therapeutic effects of new compounds and nanomaterials. Thus, it is our purpose in
this review to collect the information available related to the safety and biomedical testing
of new nanomaterials using zebrafish models, with a particular focus on their interaction
with macrophages, starting with toxicological and/or biodistribution experimentation,
followed by preclinical testing of nanoparticles for therapeutic purposes.
2. Zebrafish Innate Immune System: Role of Macrophages
The zebrafish immune system is able to develop both innate and adaptive responses.
Despite differences in anatomical sites and time points with respect to mammals. Key
cell types, molecular pathways, genetic programs, and transcription factors are highly
conserved [12]. Whereas the innate immune system components are already present in
early zebrafish embryo stages, the development of adaptive responses does not occur
until 2–4 weeks post-fertilization (wpf), and complete immunocompetence is not achieved
until 4–6 wpf [13]. Zebrafish innate immune system is composed of similar types of
cells than mammals, being macrophages the first leukocytes in development and key
players in directing the host immune response [14]. The origin of primitive macrophages
in zebrafish occurs at 14–15 h post-fertilization (hpf). These cells migrate to the yolk sac,
differentiate, and enter the circulation from 25 hpf [15,16]. The caudal hematopoietic
tissue (CHT) at two days post-fertilization (dpf), equivalent to fetal liver or placenta in
mammals, acts as a transient hematopoietic site and is a source of embryonic macrophages
and neutrophils [17,18]. The thymus produces mature T-cells and the kidney, functional
ortholog of mammalian bone marrow, produces myeloid, erythroid, thromboid, and
lymphoid cells throughout adulthood [19,20].
Macrophages are phagocytic cells from the innate immune system which can display
a wide variety of functions due to their plasticity, versatility and continuous adaptation
and response to specific stimuli [21]. In mammals, macrophages have been classically
classified according to their polarization extremes observed in the initiation or in the reso-
lution of inflammatory processes [22]. And these cells have been respectively denominated
as M1, classically activated or pro-inflammatory macrophages, versus the M2, alterna-
tively activated or wound-healing macrophages [23,24] (Figure 1). These populations have
been characterized in terms of gene expression, the pattern of surface molecules, and
the production of biological mediators and metabolites [25,26]. An imbalance between
M1 and M2 macrophages has been found in pathological tissues and correlated with
a worse prognosis of the disease (i.e., high numbers of M1-like macrophages in arthri-
tis or infiltration of M2-like macrophages in solid tumors) [21,27]. Furthermore, taking
into account this knowledge, the reprogramming of M1-like macrophages towards M2-
like anti-inflammatory effectors appears to be a reasonable strategy for the treatment of
some autoimmune diseases [23], while the stimulation of M2-like immunosuppressive
macrophages towards M1-like pro-inflammatory-anti-tumor effector cells is a promising
approach for the treatment of cancer [21,25,28–31].
Nanomaterials 2021, 11, 1784 3 of 34




Figure 1. Macrophages originate from monocytes or tissue-resident macrophages. In response to different microenvironmental 
stimuli macrophages polarize towards an M1-like or M2-like phenotype, and the excessive accumulation of macrophages with a 
particular phenotype has been correlated with a poor prognosis in some diseases (on the right). In pathological tissues, these 
macrophages frequently contribute to the development and progression of the disease, thus their reprogramming towards an 
opposite polarization status has been recognized as an important therapeutic strategy. 
In 2015, Nguyen-Chi et al. provided a seminal report on the polarization of macro-
phages in zebrafish, showing a great similarity of the M1-like and M2-like phenotypes 
with respect to mammals [32]. They used the Tg(mpeg1:mCherryF) transgenic zebrafish 
line, which enables to track macrophages [33,34], and generated the Tg (tnfa:eGFP-F) line 
to label M1-macrophages expressing tumor necrosis factor-α (TNF-α). Following fin 
wounding-induced inflammation or Escherichia coli inoculation in zebrafish larvae, they 
observed a recruitment of macrophages to the wound after amputation or to the muscle 
after bacteria-inoculation. To characterize the M1/M2 polarization, they mated both lines 
to generate the Tg(tnfa:eGFP-F/mpeg1:mCherryF), sorted mCherry+/eGFP+ and mCherry+ 
cells during the early and late phases of inflammation, and compared their RNA expres-
sion patterns, observing high levels of tnfb, il1b and il6 pro-inflammatory markers of M1-
like macrophages in double-labeled cells, while high levels of tgfb1, ccr2 and cxcr4b anti-
inflammatory markers were found in the M2-like macrophages only labeled with 
mCherry [24,32]. Similar results were obtained by Sanderson et al. using the 
Tg(irg1:EGFP)/Tg(mpeg1:mCherry) transgenic line, in which irg1 specifically labeled M1-
like macrophages upon LPS inoculation or M2-like macrophages upon injection of human 
metastatic breast cancer cells [35]. Other zebrafish-macrophage-fluorescent reporter lines, 
such as Tg(mpeg1:eGFP)gl22 [33] or Tg(mpeg1:mCherry)UMSF001 [36], have enabled to track the 
precise behavior and physiology of these cells in vivo, during inflammatory, cancer or 
infectious processes, thus providing a highly valuable tool to study their role in the con-
text of these pathologies, and also for the screening of new macrophage-targeted thera-
peutic approaches, including nanoparticles. 
  
Figure 1. Macrophages originate from monocytes or tissue-resident macrophages. In response to different microenvi-
ronmental stimuli macrophages polarize towards an M1-like or M2-like phenotype, and the excessive accumulation of
macrophages with a particular phenotype has been correlated with a poor prognosis in some diseases (on the right). In
pathological tissues, these macrophages frequently contribute to the development and progression of the disease, thus their
reprogramming towards an opposite polarization status has been recognized as an important therapeutic strategy.
, guyen-Chi et al. provided a seminal report n the polariz tion of macrophages
in zebrafish, showing a great similarity of the M1-like and M2-like phenotypes with respect
to mammals [32]. They used the Tg(mpeg1:mCherryF) transgenic zebrafish line, whic
e ables to track macrophages [33,34], and gener ted the Tg (tnfa:eGFP-F) line to label
M1-macrophages expressing tumor necrosis factor-α (TNF-α). Following fin wou ding-
ind ced inflammation or Escherichia coli inoculation in zebrafish larvae, they observed a
recruitment of macrophages to the wound after amputation or to the muscle after bacteria-
inoculation. To characterize the M1/M2 polarization, they mated both lines to generate the
Tg(tnfa:eGFP-F/mpeg1:mCherryF), sorted mCherry+/eGFP+ and mCherry+ cells during
the early and late phases of inflammation, and compared their RNA expression patterns,
observing high levels of tnfb, il1b and il6 pro-inflammatory markers of M1-like macrophages
in double-labeled cells, while high levels of tgfb1, ccr2 and cxcr4b anti-inflammatory mark-
ers were found in the M2-like macrophages only labeled with mCherry [24,32]. Similar
results were obtained by Sanderson et al. using the Tg(irg1:EGFP)/Tg(mpeg1:mCherry)
transgenic line, in which irg1 specifically labeled M1-like macrophages upon LPS inocula-
tion or M2-like macrophages upon injection of human metastatic breast cancer cells [35].
Other zebrafish-macrophage-fluorescent reporter lines, such as Tg(mpeg1:eGFP)gl22 [33] or
Tg(mpeg1:mCherry)UMSF001 [36], have enabled to track the precise behavior and physiology
of these cells in vivo, during inflammatory, cancer or infectious processes, thus providing a
highly valuable tool to study their role in the context of these pathologies, and also for the
screening of new macrophage-targeted therapeutic approaches, including nanoparticles.
3. Toxicological and Biodistribution Evaluation of Nanoparticles Using Zebrafish:
Focus on Macrophages
3.1. Toxicological Studies
The zebrafish is commonly used as an in vivo model for the toxicological evaluation
of new compounds and nanomaterials, due to its reduced cost, ease of husbandry, and
high fecundity rates [37,38]. Zebrafish and mammals present concordance in toxicological
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assays ranging from 64% to 100% [39]. Due to its short-life cycle, zebrafish can be used
to evaluate intergenerational toxicity by exposing a generation (F0) to a compound and
studying the effects on the next generations (F1, F2, etc.) [40,41]. Reproductive impairment
can also be studied by assessing sperm motility, egg depositions, and steroid hormone
levels [42,43].
The usual methods of exposure to new compounds or nanomaterials are microinjection
and immersion [44,45]. A widely used harmonized approach is the OECD Fish Embryo
Acute Toxicity (FET) Test [46]. The OECD guidelines present immersion exposure as the
preferred method and propose that tests should be performed within the first 120 hpf
(5 dpf) limit [47,48]. Nishimura et al. reviewed the methodology used in several zebrafish-
based developmental toxicity tests and indicated that 5 hpf is the preferred time to start
the exposure to a new sample, because at this point embryos are in the late blastula stage
and dechorionation can be safely performed [49]. Variations of the FET test have served
other researchers to develop assays destined to screen large libraries of compounds or to
evaluate organ-specific drug toxicities. For example, Cornet et al. took advantage of the
brief zebrafish development to combine in one test the study of cardio-, neuro-, and hepato-
toxicity effects in the same individual, enabling recompilation of organ-specific toxicity
data for 24 compounds [50]. In a different study, 91 compounds, including pesticides,
drugs, and flame retardants, were screened for teratological and behavioral effects, by
immersing dechorionated zebrafish embryos in solutions of the different chemicals [51].
In combination with in silico and in vitro assays, zebrafish models were used for the
screening of compounds with anti-inflammatory activity from a library of more than
1200 chemicals [52].
Nanotoxicological studies are commonly divided into two fields: environmental health
and nanomedicine safety [8]. In both fields, similar types of in vitro and in vivo assays
are performed, which in the case of zebrafish models take into account endpoints such as
death, hatching rate, developmental malformations, behavioral changes and gene-profiling
to assess toxicity [8,53,54]. The main factors influencing nanotoxicological effects, such as
composition, particle size, particle shape and surface charge [54], have been investigated in
zebrafish [55–57]. Zeng et al. studied the effects of Ag nanoparticles (NPs) on zebrafish and
found a decreased activity of enzymes implicated in oxidative stress, such as superoxide
dismutase, hydrogen peroxide, and malondiadehyde [55]. Another study evaluated how
the size of AgNPs could affect toxicity, revealing a higher sensitivity of zebrafish to 20 nm
AgNPs versus 100 nm AgNPs [56]. To assess the effects of shape, Abramenko et al. followed
OECD guidelines and observed that Ag nanoplates induce higher toxicity than spherical
AgNPs [57]. The toxicity of AgNPs on neural development was also evaluated through
the study of gfap and ngn1 genetic profiling [58]. The safety of other inorganic based NPs
(Au, Mg, Si, Zn) has been studied in zebrafish following similar methodologies [59–63].
Synergistic toxicity of methylmercury, SiNPs and AuNPs including surfactants have also
been evaluated in zebrafish, proving it as a useful model to explore the toxicological effects
of different compounds in the same organism [64,65]. A more comprehensive toxicological
methodology, using zebrafish, and focused on 21 endpoints, was used for the screening
of several NPs, leading to the conclusion that surface charge is a major determinant for
NP-toxicity [66].
Numerous organic-based nanomaterials have been also tested in zebrafish [67–70].
The toxicity of polyamidoamine and polypropylenimin dendrimers was tested in zebrafish
following the FET method, and with a parallel test in dechorionated embryos, showing
for both dendrimers a lower toxicity in chorionated embryos [67]. In a different study,
nanographene oxide with an external layer of polyethilenglycol was microinjected in
zebrafish to evaluate its toxicity profile and effect on angiogenesis [68]. In another study,
Teijeiro-Valiño et al. examined the toxicity of polymeric nanocapsules with an outer shell
of hyaluronic acid and protamine [69].
The interaction of NPs with macrophages was investigated using zebrafish models,
having important implications in the biocompatibility-toxicity, as well as in the biodistribu-
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tion of the NPs (reviewed in the next section) [70–74]. On one hand, NPs may trigger direct
cell toxicity through different molecular mechanisms [75], on the other hand numerous
NPs can also trigger inflammatory responses when they are recognized as foreign agents
by immune cells (i.e., macrophages) [5]. In response to NPs, the immune cells commonly
produce soluble mediators, such as cytokines, chemokines, and complement factors, which
result in the recruitment of more cells and development of acute or chronic inflammatory
responses [76]. We should also remember that, in some cases, the inflammatory cells are
capable of the biodegradation of NPs, e.g., through oxidative stress or enzymatic degrada-
tion (i.e., myeloperoxidase or eosinophil peroxidase) [77]. The balance of these responses is
of foremost importance for immunotoxicological studies. As an example, graphene oxide
immunotoxicity was evaluated by measuring glutathione, malondialdehyde, superoxide
dismutase, catalase, and genetic profiling in adult zebrafish. TNF-α, IL-1β and IL-6 ex-
pression levels were significantly increased in a dose-dependent manner [74]. Similarly,
it has been reported that several types of metallic NPs, such as gold NPs (AuNPs), silver
NPs (AgNPs), or zinc oxide NPS (ZnO-NPs), may induce oxidative stress and disrupt
signaling pathways related to innate immune responses [78–80]. Other studies involving
drugs, nanocarriers, and macrophages practiced their experiments on zebrafish [81,82].
For example, poly(lactic-co-glycolic acid) NPs (PLGA-NPs) loaded with thioridazine were
evaluated for toxicity and their therapeutic efficacy was tested in murine macrophages,
human macrophages and zebrafish models [81]. These immunotoxicological studies, using
zebrafish as in vivo model, demonstrate the relevance of safety assessment for nanomateri-
als with potential application in a variety of industrial sectors (i.e., cosmetics, paints, food
package, etc.), and they also provide pharmacological/toxicological information of interest
for their application with medical purposes.
3.2. Biodistribution
Nanotechnology is commonly used to improve the biodistribution/pharmacokinetics
of drugs. Thus, biodistribution moves from being determined by the drug’s physicochem-
ical characteristics to be dictated by the NP’s-features. Besides, by tuning the physico-
chemical properties of the NPs, a preferential accumulation in specific organs and/or cell
populations can be achieved [83]. Taking this into consideration, zebrafish is gaining impor-
tance in the nanomedicine field as a simple and reliable model to screen biodistribution of
drugs and/or NPs. The transparency of the embryos [84] and the availability of transgenic
lines offer the possibility to study in biodistribution studies the role of the interaction of
NPs at the cellular level, for example, by using macrophage-labelled embryos [85]. In this
context, different scenarios can happen depending on the aimed cellular and/or molecular
target: macrophages can be the final target for the nanomedicine, such as in the case of
autoimmune or infectious diseases, and nano-vaccines [86], or they can be a cellular popu-
lation to be avoided, due to the undesirable clearance of the therapeutic entity mediated
by these phagocytic cells, such as in the case of drugs targeted towards cancer cells or
others [72]. Of note, in the context of cancer both approaches, targeting and/or avoiding
macrophages, could be intended to improve the efficacy of certain drugs, directed towards
macrophages (i.e., immunotherapy) or to cancer cells (i.e., chemotherapy), respectively [87].
The overall biodistribution of a NP is governed by the combined effect of the admin-
istration route, the dose and the nanostructure’s composition and properties (Figure 2).
As previously described for the toxicity, the size, shape, charge and flexibility are also
critical parameters that determine the final fate of the NPs [83,88]. The circulation time of
NPs administered intravenously (i.v.) depends, mainly, on their interaction with immune
and/or endothelial cells [89]. In fact, the majority of the NPs i.v. administered are cleared in
the liver, by macrophages or by sinusoidal cells [85,90]. Part of these NPs are also captured
by circulating monocytes/macrophages, and/or other immune cells, such as neutrophils,
before reaching their target tissue, as it was recently shown for gelatine nanospheres [86]
and liposomes [91]. In zebrafish, liposomes of 60 nm showed a decreased macrophage
uptake as compared to larger 120 nm liposomes, which were more accumulated in the
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spleen [91]. Apart from immune cells, uptake by endothelial cells can also be responsible for
the limited circulation time of certain NPs. For example, polystyrene (PS) NPs of 1000 nm
were found adhered to the endothelium some minutes after the injection. On the contrary,
with a lower adherence to the endothelium, 200 nm PS NPs showed a more prolonged
circulation time. Our group evaluated the diffusion of NCs of different sizes and surface
charges in zebrafish embryos [70]. These NPs are versatile nanosystems with applications
in different fields, such as cancer, vaccination, and ocular diseases [92–95]. Both positively
and negatively charged NCs of 70 nm spread faster and at a higher extent than medium
size NCs (200 nm) after i.v. injection in zebrafish. Chitosan NCs (positively charged) were
found to be attached to the endothelial cells of the blood vessels at a higher degree than
inulin NCs (negatively charged). As a whole, zebrafish injected with the 70 nm chitosan
NCs showed the highest intensity, due to the fluorescent-NCs, in the circulatory system,
and also higher accumulation in other tissues, such as the brain and visceral organs. All
NCs showed certain degree of co-localization with GFP-labelled macrophages. However,
the positively charged NCs showed the highest accumulation in these cells. In relation
to their particle size, 200 nm NCs interacted with macrophages from early time points
(0.5 h), whereas 70 nm NCs presented less interaction at 0.5 h, but their accumulation in
these cells increased with time. From this and other studies, it can be concluded that larger
particles are commonly attached or captured by macrophages and/or endothelial cells,
thus showing shorter circulation times.
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Figure 2. Biodistribution of nanoparticles in zebrafish is related to their interaction with macrophages.
The biodistribution of nanoparticles in zebrafish embryos is mainly dictated by (A) the administration
route and (B) the physicochemical properties of the nanoparticles. Among the characteristics that
most impact the circulation time after intravenous administration are the degree of PEGylation, the
particle size, the surface charge and the shape of the particles. By tuning these properties, the uptake
by macrophages can be minimized and the circulation time can be prolonged.
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Particle shape and flexibility have also an impact on NPs biodistribution. Generally
elongated and rod-shaped NPs present a prolonged time in circulation compared with
spherical particles, especially if they are flexible [96]. This effect was observed in different
animal models (i.e., mice or pigs) [97], and also zebrafish [98]. In this case, the non-spherical
NPs were poorly taken up by macrophages because of hydrodynamic shearing. However,
other authors found that spherical NPs present prolonged circulation time versus NPs with
fibrillar morphologies upon i.v. administration in zebrafish [99]. Overall, it is important to
highlight that the final biodistribution and toxicological behaviour of a NP is orchestrated
by the interplay between its different physicochemical properties (i.e., size, charge, and
shape), and focusing only in one parameter can be misleading.
The composition of the NP’s surface and/or its functionalization with specific molecules
is also a key factor affecting its biodistribution. For instance, liposomes presented substan-
tially higher circulation time after i.v. administration in zebrafish than PS NPs of similar
size (nm) [72]. The different circulation patterns can be explained by the high affinity of PS
NPs for the endothelium, while liposomes showed a slow macrophage-mediated clearance.
With respect to decoration of NPs surface, polyethylene glycol (PEG) and other molecules
have been used to avoid macrophage interaction, while ligands for specific receptors on
macrophages-surface or other cells have been investigated. Functionalization with PEG
chains is commonly implemented to “mask” a therapeutic agent from the immune sys-
tem, reducing immunogenicity and antigenicity. PEGylated nanosystems show longer
circulation times after i.v. administration than non-PEGylated ones, by reducing their
interaction with opsonins and making NPs “invisible” to the immune system [72,89]. As an
example, liposomes commonly cleared from the circulation by macrophages, when PEGy-
lated, increased their circulation time, and their elimination by macrophages, although still
occurring, is delayed [89]. In the case of PEGylated PS NPs, the increase in their circulation
time has been attributed not only to their reduced capture by macrophages, but also to
their reduced interaction with the endothelial cells [72]. The degree of PEGylation and its
molecular weight also impacts on NPs biodistribution, showing decreased clearance by
macrophages for liposomes decorated with a higher density of PEGs or increased molec-
ular weight [91]. Other polymers with “shielding behaviour” have been used, such as
polysarcosine or poly(N,N-dimethylacrylamide), showing an increase in NP-circulation
time in zebrafish models [89].
Zebrafish models have also been used to study NP-biodistribution through other
routes of administration. Upon intramuscular (i.m.) injection in zebrafish, NPs generally
only spread along the muscle tissue close to the injection site, at least for short times [86].
As time goes by, the NPs are commonly internalized by macrophages to be cleared [86].
In our previously mentioned work, after i.m. injection, the 70 nm NCs disseminated
further than 200 nm NCs, spreading through all the myomere and limited by myosepta [70].
Positively charged NCs (chitosan based) recruited more macrophages than negatively
charged (inulin based) NCs, following a similar pattern to the i.v. route. To study the
mucosal administration of new therapies using zebrafish, NPs can be simply incubated in
water. Verrier and colleagues found that 200 nm PLA-NPs were able to cross the epithelial
barrier of different mucosae (nasal, gills, gut, and skin) and be accumulated in antigen
presenting cells, such as dendritic cells, macrophages and B cells in the gills and skin [100].
Interestingly, the NPs were able to enter the bloodstream through the gills, and to then
reach internal organs, such as the liver and kidney. Our group showed the importance of
surface composition in the ability of NCs to diffuse through the chorion before the zebrafish
hatching [69]. The presence of a PEGylated surfactant is supposed to favour the diffusion of
these NCs through the thick chorion barrier. Using hatched embryos, we demonstrated that
hyaluronic acid NCs are not able to cross the epidermis. However, protamine-hyaluronic
acid NCs were internalized and reached the yolk sac, the stomach, the esophagus and
the olfactory pit. In this case, protamine, a well-known cell penetrating peptide, could
be important to facilitate the internalization and transport through the zebrafish skin
epithelium [69]. The particle size also influences de biodistribution by the mucosal routes.
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For instance, after incubation with zebrafish in water, coumarin nanocrystals of 70 nm
showed better permeability across the chorion, blood brain barrier, blood retinal barrier and
gastrointestinal barrier than their counterparts of 200 nm. Besides, the smaller nanocrystals
accumulated at a higher extent in internal organs via lipid raft-mediated endocytosis [101].
The importance of the particle shape was demonstrated by Vijver and his group [102].
After waterborne exposure of zebrafish embryos to gold NPs of different shapes, the
macrophage’s abundance was higher for urchin-shaped NPs compared to the spherical
ones.
4. Preclinical Testing of Nanoparticles Using Zebrafish Models of Disease: Relevance
of Macrophages
4.1. Cancer
Due to its unique features, zebrafish tumor models, mainly induced by transgenesis or
xenotransplantation, are increasingly being used for cancer research and discovery of new
antitumoral drugs [103]. Xenografts are routinely performed by implantation of human or
murine cancer cells into different anatomical sites of zebrafish embryos (yolk sac, duct of
Cuvier or perivitelline space) to obtain heterotopic or eventually orthotopic in vivo tumor
models. The injection of labeled cancer cells in “transparent zebrafish” allows to track their
survival, progression, migration, and interaction with the host microenvironment [104,105].
For the transgenic models, genetically modified zebrafish lines, mainly based on the
expression of human oncogenes driven by tissue-specific or ubiquitous promoters (e.g.,
BRAFV600E, HRASG12V or KRASG12V) have been used [106–108]. While the transgenic
models are commonly preferred for the mechanistic understanding of tumor development
and/or interaction of cancer cells with the tumor microenvironment (TME), xenografts
are more used for drug screenings. As the generation of stable transgenic zebrafish lines
requires several months, it is technically challenging and less cost-effective when compared
to the simple injection of tumor cells in xenografts [109]. In addition, xenograft models have
been recently used to understand the metabolic and/or stem cell properties of cancer cells
and they also offer the possibility to study patient-derived cancer cells in vivo [110,111].
The study of macrophages in tumors is nowadays a very active field of research.
Tumors are complex tissues, comprising a heterogeneous population of cells plus the
extracellular matrix they produce, which constitute the TME [112–115]. The cellular frac-
tion is composed of malignant cancer cells, as well as endothelial cells, cancer-associated
fibroblasts, and tumor-associated macrophages (TAMs), with the latter being the latest the
most abundant cell type [116]. In human tumors, TAMs originate mostly from circulating
precursor monocytes, but resident macrophages can be originally present in the tissue,
later developing in a tumor [117]. TAM infiltration in tumor tissues has been shown to
support tumor growth, angiogenesis, invasion and metastasis, and their high density in
tumors has been correlated with tumor progression and resistance to therapies [118]. The
secretion of CSF-1, CCL2 and VEGF, by cancer cells, induce the recruitment of macrophages
towards the TME, and the Th2 cytokines IL-4, IL-13, IL-10 and TGF-β, metabolic signals
(i.e., lactic acid and hypoxia) produced also by Treg and TAMs are key drivers of im-
munosuppression [116]. With the aim to better mimic human tumors, including the TME,
zebrafish xenografts are being continuously improved, using reporter lines for analysis of
vasculature [119], neutrophils [120] and/or macrophages [32,33,35]. Orthotopic xenotrans-
plantation, consisting in the injection of tumor cells in the equivalent anatomical site, and
the use of patient-derived xenografts (PDX), allows the preservation of tumor cells’ original
phenotype, and represents a further step to recapitulate the TME and tumor cell-host
interactions [121]. The knowledge and practice acquired using these models will not only
be useful for a better understanding of tumors, but also determinant for the development
and evaluation of new antitumoral therapies [122], including nanotechnological strategies.
An enormous variety of nano-oncologicals (nanostructures for the treatment of cancer)
have been developed and evaluated with the main purpose to improve the delivery of phar-
macological molecules to the TME and reduce off-target effects [123–125]. NPs have been
designed to improve the efficacy of classical chemotherapies, immunomodulatory drugs,
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but also delicate molecules such as nucleic acids, and even new cellular therapies [126,127].
Main therapeutic strategies to target and impact on TAMs include: (i) inhibition of TAM
recruitment to the tumor, (ii) direct killing of TAMs, (iii) re-education of TAM from their
M2-like protumoral phenotype into a M1-like antitumoral phenotype [87]; offering promis-
ing opportunities to switch the tumor-promoting immune suppressive microenvironment,
characteristic of tumors rich in macrophages, to one that kills tumor cells, is anti-angiogenic
and promotes adaptive immune responses [87,128].
In this context, zebrafish models offer the possibility to test the antitumoral effect of
new nano-oncologicals, not only at the level of tumor growth in vivo [109], but also at the
cellular level within the tumor (i.e., cancer cells or TAMs in vivo). Relevant examples of
nano-oncologicals tested in zebrafish are reviewed below and summarized in Table 1.
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Table 1. Evaluation of nanoparticle-based approaches for cancer treatment using xenograft zebrafish models.





MDA-MB-231-GFP 48 hpf Duct of Cuvier Co-injection with cells
Decrease in breast cancer
cells survival [129]






MDA-MB-231-GFP 30 hpf Duct of Cuvier Pre-treatment of cancer cells Complete extinction of cancer cells [131]
PORBSNs/TPE-PDT - Porphyrin photosensitivityand ROS production
Breast cancer/






carcinoma/HeLa- CSFE 48 hpf Yolk sac Immersion/1 dpi









MCF-7-CM-DiL 48 hpf Perivitelline space Intracardiac injection/1 dpi
Feasibility of the cooperative strategy
for in vivo applications [134]
NanogelDOX DOX
Hydrazone sensitivity to pH
accelerate drug release
Melanoma/
B6-RFP or GPF 48 hpf Neural tube Intravenously/1 dpi
Selective accumulation of the NPs in




Enhanced tumor targeting by
interaction between Tf and
Tf receptor
Colorectal cancer/
HCT116-GFP 48 hpf Yolk sac Retro-orbital injection/1 dpi
Antitumoral activity without
DOX-related cardiotoxic effects [136]
PEG liposomes - - Melanoma/Melmet 5-dsRedKidney/HEK293-mCherry 48 hpf Duct of Cuvier Intravenously/2 dpi
NPs accumulation in human tumor
structure, low macrophage uptake
and high survival rate
[72]
PEG-PDPA-DOX DOX Polymersomes release thedrug only at low pH
Melanoma/
B6-RFP or GPF 72 hpf Neural tube Intravenously/1 dpi
Selective accumulation of NPs in the
tumor area, increased cancer cell
apoptosis and reduced proliferation
[137]
dpi: days post-injection; DOX: doxorubicin; PAMAM-DOX-siHIF: G4.5 polyamidoamine dendrimers loaded with DOX and hypoxia-inducible factor 1a siRNA; PAMAM-GC/DOX: G4.5 polyamidoamine
dendrimers with L-cysteine and loaded with DOX; PEG-PDPA-DOX: Poly(ethylene glycol)-block-poly(2-(diisopropyl amino) ethyl methacrylate) NPs loaded with DOX; PMOsPOR-NH2: porous porphyrin-based
organosilica NPs; PORBSNs: non-porous porphyrin-based bridged silsesquioxane NPs; PtPP-HA: kiteplatin-pyrophosphate-loaded hydroxyapatite NPs; Tf-DOX-ReSi-Au: Redox-responsive silica-gold
nanocomposites functionalized with transferrin and loaded with DOX; TPE-PDT: two-photon-excited photodynamic therapy.
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Nadar and colleagues investigated the ability of drug-loaded hydroxyapatite NPs
to release active therapeutics in vivo [129]. To this end, they used a zebrafish xenograft
model with MDA-MB-231 breast cancer cells to test the antitumoral efficacy of kiteplatin-
pyrophosphate-loaded hydroxyapatite NPs (PtPP-HA). Two days after the co-injection of
cancer cells and the platinum-loaded HA NPs into 48 hpf zebrafish blood circulation, they
found a significant decrease in survival of breast cancer cells [129]. Different types of metal
oxide-NPs, not loaded with additional pharmacological molecules, have also been tested for
antitumoral efficacy. ZnO-NPs were evaluated using a gingival squamous cell carcinoma
xenograft model, showing antitumoral activity via induction of reactive oxygen species
(ROS) and reduction of anti-oxidative enzymes with consequent oxidative damage to cells
and tissues [130,138,139]. DiL-labeled Ca9-22 cells were implanted into the yolk sac of
48 hpf Tg(fli1:EGFP) embryos and fluorescence monitoring showed no effect on survival but
dose-dependent inhibition of tumor growth [130]. The physicochemical properties of nano-
materials have also been exploited for photodynamic therapy (PDT) and tested in zebrafish.
For instance, Jimenez et al. developed, and tested in zebrafish tumor xenografts, porous
porphyrin-based organosilica NPs (PMOsPOR-NH2) [131]. At 2 dpi, treated-embryos
were subjected to two-photon-excited photodynamic therapy (TPE-PDT) and a complete
extinction of GFP-cancer cells was observed. Additionally, to analyze the efficiency of gene
delivery, the same NPs were complexed with anti-GFP siRNA and co-injected together with
GFP mRNA at one-cell stage, leading to a reduction in GFP expression a few hours later,
thus also revealing the potential use of these NPs for gene therapy. Similarly, small-seized
non-porous porphyrin-based bridged silsesquioxane NPs (PORBSNs) functionalized with
PEG and mannose (20–30 nm) were developed for i.v. injection and tested in zebrafish with
MDA-MB-231-GFP cells subjected to TPE-PDT, showing decreased tumor growth after
irradiation [132]. Moreover, with targeting purposes, Peng et al. synthesized fluorescent
cellulose acetate NPs functionalized with folate groups for their preferential accumulation
in epithelial cancer cells overexpressing folic acid receptors [140]. These NPs can be tuned
within the entire UV-VIS-NIR spectrum and were capable to target tumors in vivo. To test
the combinatorial antitumoral efficacy of chemotherapy and radiotherapy using NPs, Wu
et al. synthesized G4.5 polyamidoamine (PAMAM) dendrimers conjugated with L-cysteine
(GC), acting the later as radiosensitizer, and further loaded with doxorubicin (PAMAM-
GC/DOX) [133]. Cervical carcinoma HeLa cancer cells labeled with carboxyfluorescein
succinimidyl ester (CFSE) were injected into the yolk sac at 2 dpf. Embryos were immersed
in PAMAM-GC/DOX and further exposed to γ-radiation at 3 dpf. Synergistic antitumoral
effect for the combination chemotherapy and radiotherapy with NPs was confirmed, versus
only radiation or free DOX with or without irradiation. Likewise, PAMAM dendrimers,
functionalized with PEG using a hypoxia-induced sensitive linker, were loaded with DOX
and hypoxia-inducible factor 1a siRNA (PAMAM-DOX-siHIF) [134]. The antitumor activity
of free DOX, PAMAM+DOX, and PAMAM-DOX+si-HIF was tested upon implantation
of MCF-7-CM-DiL breast cancer cells into the perivitelline space of 48 hpf Tg(fli1:EGFP)
embryos, and intracardiac injection of free DOX, PAP+DOX and PAP-DOX+si-HIF at 1 dpi,
showing the best results for the “triple-therapeutic combination” (PAMAM-DOX+si-HIF).
Despite these promising results in zebrafish, we still foresee some limitations for the trans-
lation of some results to the clinic, in part due to the differences in zebrafish anatomy
versus mammals, because of the need for deeper penetration of radiotherapy in hidden
tumors. However, a positive experience was recently reported by Costa et al., showing the
utility of zebrafish to distinguish radiosensitive from radioresistant tumors using colorectal
cancer cell lines and patient biopsies, and clinical response was correlated with induction
of apoptosis in zebrafish [141].
Several redox- and pH-responsive-NPs have been developed, to favor the control
delivery of drugs in the reducing and acidic TME, and several zebrafish models were opti-
mized for the testing of these NPs. Transgenic mifepristone-inducible liver tumor zebrafish
line expressing the enhanced green fluorescence protein (EGFP)-Krasv12 oncogene [142],
as a model of hepatocellular carcinoma with elevated glutathione and liver acidity, was
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used [143,144]. While embryos treated with free DOX died at 2–3 dpi, lower toxicity and
sustained regression of tumor size was observed for the DOX-loaded-NPs, demonstrating
improved drug release to liver tumor cells and lower systemic toxicity [145]. A pH-sensitive
hydrazone-linked DOX nanogel (NanogelDOX) was i.v. injected in zebrafish, previously
implanted with B6 mouse melanoma cells into the neural tube at 48 hpf, showing signif-
icant reduction in tumor growth versus no effect for free DOX. [135]. Redox-responsive
silica-gold nanocomposites functionalized with transferrin and loaded with DOX (Tf-DOX-
ReSi-Au) were injected in a zebrafish colorectal cancer model, showing positive antitumoral
activity without the typical DOX-related cardiotoxic adverse effects [136]. Others have
tested the capacity of fluorescent-NPs to detect cancer cells in vivo, using similar zebrafish
tumor models [146,147].
To understand the interaction between immune and tumor cells, several zebrafish
xenograft models have been developed. These models have allowed to study the role
of immune cells in tumor vascularization and invasion [148], the dynamic interaction
between immune and cancer cells [149], or the positive correlation between the number of
immune cells recruited to the tumor site and the degree of angiogenesis [150,151]. Póvoa
et al. showed distinct engraftment profiles from the same patient at different stages of
tumor progression in colorectal zebrafish xenograft models and explored the innate im-
mune contribution to this process [152]. While cells derived from the primary tumor
were able to recruit macrophages and neutrophils, thus being rapidly cleared (regres-
sors), those cancer cells derived from a lymph node metastasis polarized macrophages
towards a M2-like protumoral phenotype, engrafting very efficiently (progressors). Inter-
estingly, mixing both types of cells resulted in decreased regressors clearance, reduced
numbers of innate cells and increased M2-like polarization. Furthermore, depletion of
macrophages resulted in a significant increase in the engraftment of regressors. These
results provide the first experimental evidence of therapeutic manipulation of macrophages
in zebrafish tumor models [152]. Detailed studies, using NPs for reprogramming TAMs
into antitumoral M1-like macrophages, have still not been performed using zebrafish
models of cancer. Nevertheless, a few investigations have explored the circulation time
of NPs, their accumulation at the tumor site and their specific uptake by macrophages
in tumors using these models. Evensen et al. were the first to image the accumulation
of NPs to human tumor-like structures in a zebrafish xenograft model [72]. Comparing
labeled polystyrene NPs and liposomes, with or without PEGylation, upon injection into
the posterior cardinal vein of 2 dpf embryos, they noted that PEG-liposomes displayed
the longest circulation time due to their lower affinity to the endothelium, the lowest
macrophage uptake, and the highest survival rate. Using xenografts, with melanoma and
kidney cancer cells, the PEG-liposomes showed a specific and rapid accumulation into
the tumor and outside the vasculature after only 2–5 h post- injection (hpi) [72]. Kocere
and colleagues demonstrated the selective accumulation of Cy5-labelled poly(ethylene
glycol)-block-poly(2-(diisopropyl amino) ethyl methacrylate) (PEG-PDPA) NPs in TAMs
using a melanoma xenograft model [137]. By injection of B6 mouse melanoma cells (la-
beled with GFP or RFP) in the neural tube of 3 dpf transgenic embryos ((Tg(fli1a:EGFP,
Tg(mpeg1:mcherry), Tg(mpx:GFP)) [33,119,153], they were able to observe tumor growth,
angiogenesis, and accumulation of macrophages, but not neutrophils, within the tumor at
10 dpf. Additionally, xenografts in 3 dpf Tg(mpeg1:GAL4/UAS:NTR-mCherry) embryos,
which express a nitroreductase in macrophages in presence of metronidazole causing
their selective apoptosis, revealed a slightly increased tumor growth when macrophages
were absent. The injection of PEG-PDPA NPs, showed selective accumulation of NPs and
increased number of macrophages at the tumor site. Moreover, a small fraction of NPs
was internalized by cancer cells and TAMs. These DOX-loaded-PEG-PDPA NPs were i.v.
injected in the melanoma model at 1 dpi, showing reduced toxicity, decreased proliferation,
and increased apoptosis of cancer cells six days after treatment [137].
As a whole, these studies provide a consistent knowledge and experience for the
development of several types of tumors in zebrafish and the testing of nano-oncologicals
Nanomaterials 2021, 11, 1784 13 of 34
with different features. Zebrafish models provide excellent opportunities for genetic mod-
ifications and for in vivo evaluation/tracking of innate immune cells, being these key
aspects for the testing of NPs. A major limitation for the use of zebrafish embryos to
test antitumoral therapies is their lack of adaptive immune system. This challenge has
partially been addressed through the suppression of the adult immune system, either by
γ-irradiation, dexamethasone treatment [154–156] or more recently using adult immuno-
compromised strains [157–159], followed by the injection of human or murine immune cells
(i.e., T cells). These adult zebrafish xenografts enable a closer resemblance of cell–tumor
microenvironment interactions, a longer tumor engraftment and a clinically-relevant dose
response [160,161]. Remarkably, Yan et al. created an optically clear, homozygous mutants
(prkdc−/−, il2rga−/−) which lacks T, B, and natural killer (NK) cells. These animals sur-
vived at 37 ◦C (optimal for mammal cells), robustly engrafted a variety of human tumor
cells and subsequently responded to drug treatments. Importantly, similar histological and
molecular features in both fish and mouse xenografts were confirmed and pharmacoki-
netics of antitumoral treatments, such as olaparib and temozolomide, were comparable
to that found in both mouse preclinical models and humans. Nevertheless, this adult im-
munocompromised strain must be improved, as several cancer cell types failed to engraft
into the model and pre-treating fish with clodronate liposomes to deplete macrophages
was required [159]. Additional disadvantages of zebrafish models are that some strains
do not breed, develop gill inflammation, and likely autoimmunity [158], or they could be
quite prone to infection and require specialized food and antibiotic treatment [162], thus
raising the cost of maintenance. Despite these challenges, the results demonstrate that
zebrafish tumor models are important tools with high potential to improve the translation
of nano-oncologicals towards the clinic.
4.2. Autoimmune Diseases
4.2.1. Inflammatory Bowel Disease
Inflammatory bowel diseases (IBDs) refer to chronic inflammatory disorders of the
gastrointestinal tract which comprise both Crohn’s disease and ulcerative colitis. Although
their etiology is not clear, they are thought to be a result of host genetic susceptibility and
environmental factors (e.g., diet) [163,164], which lead to altered interactions between gut
microbiota and the intestinal immune system [165]. Intestinal homeostasis is partly main-
tained by resident macrophages with enhanced phagocytic and bactericidal activity and
decreased production of pro-inflammatory cytokines [166]. Nevertheless, when gut dysbio-
sis and further disruption of normal mucosal immunity occur, monocytes are continuously
recruited to become inflammatory macrophages, they participate in the inflammatory
response and contribute to chronic intestine inflammation [167]. In this context, zebrafish
models are useful to study the relationship between immune system and inflammation. For
instance, Coronado et al. treated fish with a previously established inflammatory diet [168]
and found a strong increase in the number of neutrophils, macrophages and T helper cells
recruited to the gut [169]. Looking into the genetic susceptibility, Kaya et al. were able to
validate the implication of GPR35-expressing macrophages in intestinal immune home-
ostasis and inflammation by generating a zebrafish mutant line [170]. Other researchers
have shown the potential of zebrafish for the screening of drugs to treat IBDs [171–173].
With regard to NPs, to date, we only found one study where the administration of copper
NPs to zebrafish resulted in intestinal developmental defects, through ER stress and ROS
generation, showing similar alterations to IBD patients (Table 2) [174]. Thus, these studies
provide the starting point for the study of IBD pathology and testing of NPs which might
offer new solutions to patients suffering these intestinal disorders.
4.2.2. Type I Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is an autoimmune disease caused by immune-
mediated progressive destruction of the pancreatic β-cells, driven by the interaction of
multiple environmental and genetic factors. The pathogenesis of T1DM is characterized
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by the infiltration of islet antigen-specific T cells and pro-inflammatory APCs associated
with impairment of Foxp3+ Tregs. The destruction of β-cells leads to the loss of ability
to produce insulin and in turn, to chronic hyperglycemia [175,176]. T1DM treatment is
mainly based on lifelong insulin replacement therapy and several nanoparticles have been
designed to improve its administration [177,178]. Others have explored the inhibition of
the destructive autoimmune response against insulin-producing β-cells, for example by
regulating T-cell autoreactivity as a therapeutic approach [179,180]. In zebrafish models, to
mimic T1DM, the destruction of β-cells has been achieved by either surgery [181], chemical
destruction [182], or genetic ablation [183], followed by their subsequent regeneration
ability allowing to study the mechanisms of β-cells regeneration and also the testing of
antidiabetic drugs [184,185]. A number of chemical screens to induce β-cell generation in
zebrafish have been reported [186–188] and the antidiabetic effect of different bioactive
molecules and NPs has been tested (Table 2).
Silver nanoparticles loaded with Eysenhardtia polystachya (EP/AgNPs), with a spheri-
cal shape and diameter of 5–21 nm, were tested on glucose-induced diabetic adult zebrafish
and the results confirmed the effectiveness of NPs in ameliorating hyperglycemia [189].
The utility of quercetin NPs (NQs) in ameliorating diabetic retinopathy, a common compli-
cation derived from diabetes was shown by Wang et al. [190]. Chemically induced diabetes
and diabetic retinopathy were established in adult zebrafish, and further treatment with
NQs led to a reduction in glucose blood levels as wells as to the improvement of differ-
ent morphological, behavioral, and biochemical parameters linked to diabetic retinopa-
thy [190]. Others have evaluated the biocompatibility/toxicological profile of different
types of NPs with potential antidiabetic activity, such as peptide-major histocompatibility
complexes-NPs or curcumin encapsulated in polycaprolactone-grafted oligocarrageenan
nanomicelles [191,192]. These studies provide a solid basis for the further use of zebrafish
models to screen new antidiabetic nanotechnological approaches.
4.2.3. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory and autoimmune disease charac-
terized by synovial and joint swelling, pain, and bone destruction [193]. The pathogenesis
of RA is a multistep process, initially starting outside the joints by the aberrant activation
of antigen-presenting cells, triggered by genetic or environmental causes, which leads
to the activation of a pro-inflammatory cascade, production of autoantibodies as well as
altered T-cell and B-cell cross-activation [194,195]. These events lead to monocyte recruit-
ment to the diseased tissue and activation and polarization of macrophages towards a
M1-like pro-inflammatory phenotype, boosting the inflammatory cascade [196]. Current
RA-treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids,
disease-modifying antirheumatic drugs, and different natural substances to reduce joint
inflammation [197]. With the aim to mimic human disease, improve its understanding
and test new therapies, several animal models have been developed [198,199], and ze-
brafish models could be also implemented as a useful tool. Zebrafish have served as a
model to evaluate the anti-inflammatory properties of different synthetic and natural com-
pounds, although no reports on nanomaterials are available yet. Clerodendrum cyrtophyllum
Turcz is a commonly used plant in Vietnam for treating RA. Ngyuyen et al. confirmed
the anti-inflammatory properties of ethanol extracts of this plant in a copper-induced
inflammation zebrafish model, via downregulation of inflammation mediators and pro-
inflammatory cytokines (e.g., cox-2 or il-1β) [200]. Similarly, Jiang et al. demonstrated
anti-inflammatory effects of isothiocyanate prodrugs in a zebrafish neutrophilic inflam-
mation model, as the number of migrating neutrophils in treated zebrafish was smaller
than in the control group [201]. Wang et al. demonstrated the inhibition of cyclooxygenase,
as the anti-inflammatory mechanisms of action of Gentiana dahurica roots, in a zebrafish
model of induced production of cyclooxygenases 1 and 2 [202]. Genetic approaches using
zebrafish were applied to study the role of c5orf30, whose variants have been associated
with RA. Upon tail transection in the c5orf30 knockdown fish an increased recruitment
Nanomaterials 2021, 11, 1784 15 of 34
of macrophages to the wound site was observed, confirming the anti-inflammatory role
of c5orf30, with implications in RA [203]. With reference to early diagnosis, Feng et al.
designed and synthesized fluorescent probes for the quantitative detection of hypochlorous
acid, a biomarker of RA, and confirmed their efficiency in an LPS-induced inflammatory
model of adult zebrafish [204]. Additionally, zebrafish has served as a platform to evalu-
ate the toxicity of new treatments with potential application in RA [205,206]. Although
mammalian models of RA are needed before the clinical translation of new therapeutic
approaches, these zebrafish models provide a valuable tool for the initial screening of
innovative nanotechnological approaches to treat RA.
4.2.4. Neuroinflammatory and Neurodegenerative Diseases
Several zebrafish models have been established and optimized for the understanding
of neuroinflammatory or neurodegenerative diseases [207,208]. In parallel, different types
of NPs have been engineered for the treatment and/or diagnosis of neuro-related disor-
ders [209,210]. Interestingly, zebrafish models have also been used to study the neurotoxic
or neuroprotective effects of a wide variety of NPs and biomaterials [207]. Below, we
provide some examples of investigations using zebrafish models and NPs to improve drug
targeting and/or efficacy in the context of neuroinflammatory and neurodegenerative
diseases (Table 2).
Neuroprotective effects of NPs in Parkinson’s disease (PD) using zebrafish models
have been observed, commonly mediated by the antioxidant and/or neuro-antiinflammatory
activity of these NPs. Bacopa monnieri platinum NPs (BmE-PtNPs) demonstrated the
same activity of Complex I, as that of oxidizing NADH to NAD(+), suggesting that BmE-
PtNPs could be a potential medicinal substance for oxidative stress mediated disease with
suppressed mitochondrial complex I as it happens in PD. Hence, in 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinsonism in zebrafish model,
BmE-PtNPs pretreatment significantly reversed the toxic effects of MPTP by increasing
the levels of dopamine, its metabolites, GSH, and activities of GPx, catalase, SOD and
complex I, and reducing levels of MDA along with enhanced locomotor activity [211].
Schisantherin A (SA) is a promising anti-Parkinsonism Chinese herbal medicine and SA
nanocrystals (SA-NC) were used to reverse the MPTP-induced dopaminergic neuronal loss
and locomotion deficiency in zebrafish. This strong neuroprotective effect of SA-NC may
be partially mediated by the activation of the protein kinase B (Akt)/glycogen synthase
kinase-3β (Gsk3β) pathway [212]. On the other hand, it has been shown that, after expo-
sure of different concentrations of titanium dioxide NPs (TiO2 NPs) to zebrafish embryos
from fertilization to 96 hpf, the hatching time of zebrafish was decreased accompanied by
an increase in malformation rate, while no significant increases in mortality relative to con-
trols were observed [213]; moreover, accumulation of TiO2 NPs was found in the brain of
zebrafish larvae, resulting in loss of dopaminergic neurons, ROS generation and cell death
in hypothalamus. Meanwhile, q-PCR analysis showed that TiO2 NPs exposure increased
the pink1, parkin, α-syn, and uchl1 gene expressions, which are related with the formation of
Lewy bodies [213]. Data from zebrafish behavioral phenotype revealed observable effects
of silica nanoparticles (SiNPs) on disturbing light/dark preference, dampening exploratory
behavior and inhibiting memory capability; furthermore, the relationship between neuro-
toxic symptom and the transcriptional alteration of autophagy- and parkinsonism-related
genes was showed [62]. Similarly, another study showed that 15-nm silica SiNPs produced
significant changes in advanced cognitive neurobehavioral patterns (color preference) and
caused PD-like behavior compared with 50-nm SiNPs. Analyses at the tissue, cell and
molecular levels corroborated the behavioral observations [214]. Both studies demon-
strated that nanosilica acted on the retina and dopaminergic neurons to change color
preference and to cause PD-like behavior [62,214]. Puerarin has emerged as a promising
herb-derived anti-Parkinsonism compound and puerarin nanocristals (PU-NCs) demon-
strated no obvious toxic effects on zebrafish, as evidenced by the unaltered morphology,
hatching, survival rate, body length, and heart rate; fluorescence resonance energy transfer
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(FRET) imaging revealed that intact nanocrystals were found in the intestine and brain
of adult zebrafish [215,216]. Moreover, other NPs with alleged neuroprotective effects for
treating PD, such as polymeric NPs of Ginkgolide B, have shown correct bioavailability
and cerebral accumulation in zebrafish models [217].
Similarly, as with PD, some authors have shown neuroprotective and neuroregen-
erative effects of different NPs in Alzheimer’s disease (AD) zebrafish models. Thereby,
it has been shown that casein coated-gold nanoparticles (βCas AuNPs) in systemic cir-
culation translocate across the blood brain barrier (BBB) of zebrafish larvae, sequester
intracerebral Aβ42 and its elicited toxicity in a nonspecific chaperone-like manner. This
was evidenced by behavioral pathology, ROS, and neuronal dysfunction biomarkers assays,
complemented by brain histology and inductively coupled plasma-mass spectroscopy.
The capacity of βCas AuNPs in recovering the mobility and cognitive function of adult
zebrafish exposed to Aβwas demonstrated [218]. Other study evaluated the role of solid
lipid NPs of quercetin (SLN-Q), a flavonoid with multiple pharmacological actions like vas-
cular integrity and regulatory action on the BBB, using pentylenetetrazole (PTZ) induced
cognitive impairment of Danio rerio species [219]. The intraperitoneal pretreatment of SLN-
Q showed an attenuating effect in PTZ induced neurocognitive impairments, along with
amelioration of biochemical changes (acetylcholinesterase activity, lipid peroxidation, and
reduced glutathione levels), showing differences with fish treated with donepezil. Some
authors have demonstrated with confocal image analyses that amphiphilic yellow-emissive
carbon dots (Y-CDs) crossed the BBB of five-day old wild-type zebrafish, most probably by
passive diffusion due to the amphiphilicity of Y-CDs; furthermore, Y-CDs were internalized
by the cells, inhibiting the overexpression of human amyloid precursor protein (APP) and
β-amyloid (Aβ) which is a major factor responsible for AD pathology [220].
Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease affecting the
upper and lower motor neurons in the motor cortex and spinal cord, could be ameliorated
by reducing the levels of superoxide dismutase I (SOD1). Thus, calcium phosphate lipid
coated nanoparticles (CaP-lipid NPs) were developed and tested in zebrafish for the
delivery of SOD1 antisense oligonucleotides (ASO) with success, and their preferential
accumulation in the brain, blood stream, and spinal cord was observed [221].
In addition, the toxic profile of several NPs with potential interest for neurological
diseases was also evaluated using zebrafish models. As examples, Carbamazepine or
Tacrine were co-administered with PAMAM dendrimers and neurotoxicity, cardiotoxicity,
or hepatotoxicity were evaluated in zebrafish larvae [222,223]. These reports provide
satisfactory experience in the study of neuro-related disorders using zebrafish models and
a good basis for their use as a screening platform to support new nanotechnologies for the
treatment of these diseases.
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Table 2. Summary of nanoparticles tested in zebrafish models of autoimmune diseases: inflammatory bowel disease, type I diabetes mellitus, parkinson’s disease, alzheimer’s disease,
amyotrophic lateral sclerosis.
Disease Disease Induction Zebrafish Stage Nanosystem NPs Delivery Remarkable Results Reference
Inflammatory Bowel Disease Copper NPs- induced intestinaldevelopmental defects From 0 hpf Copper NPs Immersion
CuNPs cause intestinal developmental defects via inducing ER stress
and ROS generation, which corresponds with elevated serum copper
levels in IBD patients
[174]
Type 1 diabetes mellitus Glucose-induceddiabetic zebrafish Adult EP/AgNPs Immersion Hyperglycemia amelioration [189]
Type 1 diabetes mellitus STZ- induceddiabetic retinopathy Adult Quercetin NPs Intraperitoneal injection
Reduction of glycemia and improvement of morphological,
behavioral and biochemical parameters linked to retinopathy [190]
Type 1 diabetes mellitus - From 4 hpf pMHC-NPs Immersion Neither off-target toxicity, nor morphological abnormalities [191]
Parkinson’s Disease MPTP-induced parkinsonism Adult BmE-PtNPs Intraperitoneal injection
Significant reversion of toxic effects of MPTP by increasing the levels
of dopamine, GSH, GPx, catalase, SOD and complex I, and reducing
levels of MDA
[211]
Parkinson’s Disease MPTP-induced parkinsonism From 72 hpf Schisantherin nanocrystals Immersion Reversed dopaminergic neuronal loss and locomotion deficiency bythe activation of the Akt/Gsk3β pathway [212]
Parkinson’s Disease - From 0 hpf Titanium dioxide NPs Immersion Loss of dopaminergic neurons, ROS generation and cell death inhypothalamus. Increased Lewy bodies-related markers. [213]
Parkinson’s Disease - Adult Silica NPs Immersion
Changes in dopaminergic neurons with disturbed light/dark
preference, dampened exploratory behavior, inhibited memory
capability and PD-like behavior
[62,214]
Parkinson’s Disease - From 6 hpf Puerarin Nanocristals Immersion Promising anti-Parkinsonism NCs. Unaltered morphology, hatching,survival rate, body length and heart rate [215,216]
Parkinson’s Disease - From 120 hpf Ginkgolide B-PEG-PCL NPs Immersion Correct bioavailability and cerebral accumulation inzebrafish models [217]
Alzheimer’s Disease Aβ- induced toxicity Adult Casein coated-gold NPs Retro-orbital injection Inhibition of Aβ toxicity and recover of the mobility andcognitive function [218]
Alzheimer’s Disease PTZ- inducedcognitive impairment Adult Solid lipid NPs of Quercetin Intraperitoneal injection
Attenuation of PTZ-induced neurocognitive impairments and
amelioration of biochemical changes [219]
Amyotrophic Lateral Sclerosis - From 96 hpf ASO- CaP-lipid NPs Brain, spinal cord, intravenousand retro-orbital injection
Successful delivery and preferential accumulation in brain,
bloodstream and spinal cord [221]
APP: Human amyloid precursor protein; ASO-CaP-lipid NPs: SOD1 antisense oligonucleotide-calcium phosphate lipid coated NPs; Aβ: β-amyloid; BmE-PtNPs: Bacopa monnieri platinum NPs; EP/AgNPs:
Eysenhardtia polystachya-loaded silver NPs; ER: Endoplasmic reticulum; GSH: Glutathione; GSH-Px: Glutathione peroxidase; MDA: Malondialdehyde; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; STZ:
Streptozotocin; PEG-PCL NPs: Poly(ethylene glycol)-co-poly(ε-caprolactone); pMHC-NPs: Peptide-major histocompatibility complexes NPs; PTZ: Pentylenetetrazole; SOD: Superoxide dismutase.
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4.3. Infectious Diseases
Zebrafish models have been largely used to study infectious diseases, taking ad-
vantage of its transparency, possibilities to study both innate and adaptive immunity,
and feasibility for the highly controlled administration of pathogens, commonly through
microinjection. Prospective treatments are mostly administered by microinjection too,
although other routes such as intubation have been described [224]. Most of the studies
reviewed in this section have been performed using zebrafish in the first month of life,
which does not present a completely developed adaptive immune system but allows for
the separate study of macrophages and neutrophils during pathogenic infection [225,226].
Transgenic lines that attach fluorescent proteins to robust macrophages markers, such as
mpeg1 or csf1ra, have been used [227]. As an example, Palha et al. infected Tg(fnϕ1:mCherry)
zebrafish larvae with two Chikungunya virus strains, one of which expressed GFP, allow-
ing to follow infection progress and its quantification by flow cytometry. This work,
using zebrafish, demonstrated similarities with the process in mammals and a critical
role of the IFN response to control the infection. Furthermore, the differential role of
macrophages and neutrophils was investigated using a transgenic metronidazole-inducible
cell ablation system to deplete macrophages. Neutrophil depletion was studied in csf3r
knockdown larvae that were highly susceptible to Chikungunya virus, exhibiting a high
increase of virus transcripts and mortality [228]. In another study, selective depletion of
macrophages by incubation in metronidazole reduced the virulence of infection caused
by the Burkholderia cepacia complex, revealing the important role of these cells in the in-
fectious process [229]. The easiness for monitoring macrophages in zebrafish allowed
extensive studies of tuberculosis and facilitated the observation of granulomas caused by
Mycobacterium marinum [230–232]. Clay et al. took advantage of the transparency of the
zebrafish to report a dichotomous role of macrophages in early M. marinum infection. First,
they performed dual fluorescent antibody detection of L-plastin and myeloperoxidase to
confirm that only macrophages and not neutrophils phagocytose bacteria. Most bacteria
were found in macrophages (L-plastin positive but MPO-negative). Second, they assessed
whether macrophages upregulate inflammatory cytokines as a response to M. marinum.
They injected separately the bacteria and similar-sized fluorescent beads into the hindbrain,
demonstrating that macrophages migrated to the area in response to M. marinum but
not in response to the beads. Macrophage-defective zebrafish embryos were created by
the injection of morpholinos against the pu.1 gene to evaluate the role of macrophages
on mycobacterial growth. Finally, the Tg(fli1:EGFP) transgenic line and pu.1 morphants
were used to study bacteria dissemination through the vascular system and the role of
macrophages. By injecting red fluorescent bacteria into the bloodstream, they found that
control embryos had a higher number of extravascular bacteria than pu.1 morphants and
bacteria injected in the hindbrain could only disseminate out of this space in the control
zebrafish with macrophages [231]. Similarly, Davis and Ramakrishnan exploited zebrafish
transparency to assess the role of macrophages in tuberculous infection through three-
dimensional differential interference contrast microscopy (3D DIC) and fluorescence in vivo
microscopy. Embryos were infected with wild type and attenuated M. marinum, lacking the
ESX-1/RD1 secretion system locus, throughout their experiments. Upon injection of the
bacteria into the hindbrain ventricle and daily monitoring, infected macrophages recruited
uninfected macrophages in a RD1-dependent manner. Further, the combination of 3D
DIC with time-lapse microscopy showed that uninfected macrophages become infected
quicker when they are recruited by RD1-competent bacteria. Zebrafish transparency also
enabled close observation of the macrophage’s morphology both in WT and RD1 defective
bacteria, which proved to be different. Finally, after proving that macrophages become
infected when phagocyting dead infected macrophages, granuloma dissemination initiated
by macrophages from primary granulomas was also observed. To assess the migration of
infected macrophages, they used a bacteria strain that constitutively expresses the Kaede
photoactivable protein [232]. Other pathogens relevant for humans (Candida albicans, Herpes
simplex, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumonia) [233–236]
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and fish (Vibrio anguillarum, Aeromonas salmonicida, Yersinia ruckeria, etc.) [237–239] have also
been studied using zebrafish models [240,241]. In relation with the study of tuberculosis,
Oksanen et al. demonstrated that zebrafish is a useful model for preclinical DNA vaccine
development. They vaccinated zebrafish with a combination of plasmids encoding for
Ag85B, CFP-10, and ESAT-6, well known mycobacterial antigens, through intramuscular
microinjection. Three weeks after immunisation, zebrafish were challenged with a high
dose of M. marinum (20,500 CFU) by microinjection. Vaccinated fish showed increased
survival and the analysis of the bacterial load by qPCR revealed that unvaccinated ze-
brafish had a higher load than the vaccinated group [242]. Taken together these studies are
proof of the versatility of zebrafish to study pathogen infection and dissemination in vivo.
Genetic-wise, besides an already existing repertoire of transgenic lines, Clay et al. proved
D. rerio can be tailored to the needs of the researchers for the study of macrophages by the
knockdown of key regulator genes [231].
Several nanotechnology-based-approaches have been developed for vaccination, pro-
phylactic and therapeutic purposes, in the context of infectious diseases, and tested in
zebrafish models (Table 3). With prophylactic purposes, Torrealba et al. generated inclusion
bodies (IBs) containing TNFα or CCL4 [243]. The resulting nanostructures (IBs) showed
good stability under different pH conditions (2.5 and 8). While IBTNFα were cylindrical with
a diameter between 380–900 nm and an average length of 1134.6 ± 196.6 nm, the IBCCL4
showed spherical shape with a diameter between 220–850 nm. Both IBs were added to the
cell culture of ATTC® CRL-2643 (zebrafish liver cells) and RT-HKM (trout macrophages) to
evaluate their uptake, showing positive results for both cell types. Further, treatment of
RT-HKM with IBTNFα stimulated the expression of pro-inflammatory cytokines. In vivo,
zebrafish were immunised with IBTNFα, IBCCL4, or IBiRFP-H6 (an IB containing a control
protein) by microinjection and later challenged with P. aeruginosa. Zebrafish injected in-
traperitoneally with both types of IBs exhibited reduced mortality after a challenge with P.
aeruginosa. Similar inclusion bodies were also used to encapsulate proteins of pancreatic
necrosis virus (IPNV), haemorrhagic septicaemia virus (VHSV) and viral nervous necro-
sis virus (VNNV) for the development of oral prophylactics [224]. IPNV-IBs were barrel
shaped and porous with an average width and length of 607 and 734 nm, respectively.
VHSV-IBs were round with a width and length of 488 and 608 nm. VNNV-IBs presented an
irregular shape with spherical protrusions and a mean diameter of 422 nm. Gene expression
analysis of trout macrophages stimulated in vitro with IPNV-IBs and VHSV-IBs showed
upregulation of pro-inflammatory markers: vig1, gig2, stat1b, mx, irf7, and ccl4. In vivo
uptake of the fluorescently labelled IBs was evaluated by intubating zebrafish adults with
the IBs solutions and later analysing gut cells by flow cytometry. Uptake of VHSV-IBs
or VNNV-IBs was observed by all fish, while IPNV-IBs were only taken up by 75% of
fish. In another study, various recombinant vaccines based on glycoprotein G of viral
haemorrhagic septicaemia virus encapsulated in NPs were developed. NPs were produced
by complexing poly(I:C) with chitosan, size ranged from 100 to 550 nm with an average
diameter of 368 ± 1.3 nm and an average surface charge of +36.2 mV. Fish vaccinated
with NPs containing poly(I:C) showed lower mortality rates than non-vaccinated fish or
fish vaccinated with NPs without poly(I:C) [244]. Chitosan was also used as a polymer to
coat Piscirickettsia salmonis membrane nanovesicles for immunisation. The chitosan-coated
NPs showed an average diameter of 182.2 ± 4.3 nm and a Z-potential of 31.2 ± 1.8 mV.
Immunisation was successful and the upregulation of immune related genes (IL-8, IL-1β,
IL-10, and IL-6) was reported by analysis of kidney samples [245]. In essence, these articles
provide evidence for the use of adult zebrafish as a valid model for immunological studies
and as an economic platform for the testing of nano-based approaches designed to improve
fish survival, which is of particular interest in aquaculture.
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Table 3. Summary of nanoparticles tested in zebrafish models of infectious diseases.
Disease Induction Zebrafish Stage Nanosystem NPs Delivery Immune Cells Behavior Remarkable Results Reference
Pseudomonas aeruginosa infection Adult
Nanostructured cytokines
(IBTNFα, IBCCL4)
Intraperitoneal injection Interaction of IBs withimmune cells Prophylactic potential in vivo [243]
- Adult IPNV, VHSV andVNNV-encapsulated IBs Oral intubation -






Intraperitoneal injection Upregulation ofantiviral cytokines
Significant protection against VHSV through
induction of anti-viral state [244]
Piscirickettsia salmonis infection Adult Chitosan-coated MVs fromP. salmonis Intraperitoneal injection
Upregulation of immune
related genes
Successful immunisation. Potential use of
chitosan-coated MVs for vaccination [245]
Streptococcus pneumonia infection From 48 hpf Auranofin-PLGA-NPs Immersion - Auranofin-NPs capability of decreasing thebacterial population compared to free drug [246]
IBs: Inclusion bodies; IPNV: Pancreatic necrosis virus; VHSV: Viral hemorrhagic septicemia virus; VNNV: Viral nervous necrosis virus; MVs: Membrane nanovesicles; PLGA-NPs: Poly(lactic-co-glycolic acid)
NPs; LPS: Lipopolysaccharide.
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In the search for anti-bacterial compounds to deal with antibiotic resistance, Díez-
Martínez et al. assayed the anti-bacterial effect of Auranofin, an FDA-approved drug for
the treatment of rheumatoid arthritis, free and encapsulated in nanocapsules of poly(lactic-
co-glycolic acid) (PLGA-NPs) in vivo using a zebrafish infection model of Streptococcus
pneumoniae. PLGA-NPs loaded with Auranofin were spherical with a diameter of 60 nm
and a negative surface charge (−30mV). Then, 48 hpf zebrafish embryos were infected by
immersion with the pathogen and later treated with free auranofin or auranofin-PLGA-
NPs, again by immersion. Encapsulated auranofin was more efficient at rescuing infected
embryos in a dose dependent manner than the free drug. Moreover, when compared
with encapsulated ampicillin, auranofin PLGA-NPs were still more efficient at increasing
survival rates of infected fish [246]. As a cheap, high-throughput model organism, zebrafish
could greatly contribute to the initial development of new approaches in the fight against
antimicrobial resistance.
Taken together, these findings demonstrate that zebrafish models are very useful
for the study of infectious diseases and for the testing of new therapeutic approaches,
including NPs. As described above, the evaluation of macrophage and/or neutrophil
behavior in this context is of foremost interest, and zebrafish models offer an appropriate
environment to study the role of these innate immune cells along the course of the disease
and in response to treatment.
5. Conclusions
In the last years, the use of zebrafish models in biomedical research has increased
substantially to study the cellular and/or molecular basis of human diseases, and for the
faster and more economic testing of new compounds, drugs, biomaterials, and nanoparti-
cles. In Figure 3, we can clearly observe the rising number of studies published each year,
including zebrafish or nanomaterials, related to toxicity, biodistribution, macrophages,
cancer, infectious diseases, or other autoimmune disorders. Manuscripts with a focus
on toxicity, macrophages, and cancer are the most frequent, and their number has been
consistently increasing in the last decade. Only a few nanomaterials have still been tested
in zebrafish models, but the number of this type of studies is also clearly increasing.
In addition to economic and ethical issues, zebrafish models provide excellent oppor-
tunities for genetic modifications and for in vivo evaluation/tracking of innate immune
cells, such as macrophages. Such unique features make zebrafish amenable to a multitude
of methodologies and the establishment of disease models which have already proven vi-
able to study the interaction of macrophages with nanoparticles. These technical advances
have been used for a precise toxicological and/or biodistribution testing of nanomaterials
with safety or medical purposes. Following a similar trend, we foresee an increase in the
testing of nanotechnological approaches for the treatment of cancer, infectious disease, or
other autoimmune disorders, using zebrafish models of disease, and providing further
information about the role of macrophages in the initiation, progression, and remission of
the disease over the course of the treatment. Ultimately, we expect that these studies will
contribute to the safe use of nanotechnologies and to their translation towards the clinic,
providing new solutions for patients.
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PEG Polyethylene glycol
PEG-PCL NPs Poly(ethylene glycol)-co-poly(ε-caprolactone) NPs
PEG-PDPA NPs Poly(ethylene glycol)-block-poly(2-(diisopropyl amino) ethyl
methacrylate) NPs
PLA NPs Poly(Lactic Acid) NPs
PLGA-NPs Poly(lactic-co-glycolic acid) NPs
pMHC-NPs Peptide-major histocompatibility complexes NPs
PMOsPOR-NH2 Porous porphyrin-based organosilica NPs
PORBSNs Non-porous porphyrin-based bridged silsesquioxane NPs
PS Polystyrene




RFP Red fluorescent protein
ROS Reactive oxygen species
SA-NCs Schisantherin nanocrystals
siHIF Hypoxia-inducible factor 1a siRNA
SiNPs Silica NPs
SLN-Q Solid lipid NPs of quercetin
SOD Superoxide dismutase
STZ Streptozotocin
T1DM Type 1 diabetes mellitus
TAMs Tumor-associated macrophages
Tf-DOX-ReSi-Au Redox-responsive silica-gold NPs functionalized with
transferrin- DOX
TGF-β Transforming growth factor-β
TiO2 NPs Titanium dioxide NPs
TME Tumor microenvironment
TNF-α Tumor necrosis factor-α
TPE-PDT Two-photon-excited photodynamic therapy
VEGF Vascular endothelial growth factor
VHSV Viral hemorrhagic septicemia virus
VNNV Viral nervous necrosis virus
wpf Weeks post-fertilization
Y-CDs Amphiphilic yellow-emissive carbon dots
ZnO-NPs Zinc oxide NPs
βCas AuNPs Casein coated-gold NPs
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